Bana Sanjana, Daffara Sia, Dagar Aastha, Tiwari Ashutosh Kumar, Medhi Kanupriya, Mukherjee Sagarika, Uttam Vivek, Ansari Md Rizwan, Tuli Hardeep Singh, Yadav Vikas, Jain Aklank
Non-Coding RNA and Cancer Biology Lab, Department of Zoology, Central University of Punjab, Ghudda, Bathinda 151401, Punjab, India.
GD Research Center, 3rd Floor, Jyoti Pinnacle Building, Survey No.11, Kondapur Village, Serilingampally Mandal, Ranga Reddy District, Hyderabad 500081, Telangana, India.
Diseases. 2025 Mar 20;13(3):89. doi: 10.3390/diseases13030089.
Pancreatic (PC), colorectal (CRC), hepatocellular (HCC), and gallbladder (GC) cancers together account for nearly 20% of all cancer cases. However, specific biomarkers and therapeutic targets for these cancers are lacking. Diagnosing these cancers early and providing timely, appropriate treatment to improve patient outcomes is crucial. In this context, previous studies, including ours, have highlighted the potential of non-coding RNAs, particularly long non-coding RNAs (lncRNAs), in diagnosing and prognosis of various cancers. This review focuses on the mechanistic role of the recently identified lncRNA in PC, CRC, HCC, and GC. Our comprehensive literature analysis revealed that functions as a tumor suppressor, and its reduced expression is associated with larger tumor size, advanced tumor-node-metastasis (TNM) stages, lymphatic metastasis, and poorer overall survival rates. Additionally, we discovered that acts as a molecular sponge for miRNAs, such as miR-550a-3p, miR-23a-3p, miR-148a, miR-324-3p, and miR-105-5p, regulating critical cancer-related signaling pathways, including PI3K/Akt/mTOR, Protein kinase B, and Mammalian target of rapamycin (mTOR). Further bioinformatic analysis revealed that regulates key cellular processes, such as protein-DNA complex formation, ribonuclease complex activity, histone deacetylase complexes, and nuclear matrix interactions. Overall, we believe that holds significant promise as a future biomarker and, when combined with existing treatment strategies, may enhance cancer patient care and survival.
胰腺癌（PC）、结直肠癌（CRC）、肝细胞癌（HCC）和胆囊癌（GC）合计占所有癌症病例的近20%。然而，这些癌症缺乏特异性生物标志物和治疗靶点。早期诊断这些癌症并提供及时、恰当的治疗以改善患者预后至关重要。在此背景下，包括我们的研究在内，以往的研究突出了非编码RNA，尤其是长链非编码RNA（lncRNAs）在各种癌症诊断和预后方面的潜力。本综述聚焦于最近发现的lncRNA在胰腺癌、结直肠癌、肝细胞癌和胆囊癌中的作用机制。我们全面的文献分析表明， 发挥肿瘤抑制作用，其表达降低与更大的肿瘤大小、晚期肿瘤-淋巴结-转移（TNM）分期、淋巴转移及更差的总生存率相关。此外，我们发现 充当miR-550a-3p、miR-23a-3p、miR-148a、miR-324-3p和miR-105-5p等miRNA的分子海绵，调节关键的癌症相关信号通路，包括PI3K/Akt/mTOR、蛋白激酶B和雷帕霉素靶蛋白（mTOR）。进一步的生物信息学分析表明， 调节关键的细胞过程，如蛋白质-DNA复合物形成、核糖核酸酶复合物活性、组蛋白脱乙酰酶复合物和核基质相互作用。总体而言，我们认为 作为未来的生物标志物具有巨大潜力，并且与现有治疗策略相结合时，可能会改善癌症患者的护理和生存率。
